A Phase 3 interventional study of Steroid eye drops and Vasoconstrictor eye drops in Glioblastoma Multiforme, sponsored by AbbVie. Terminated at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Glioblastoma by AbbVie — none open to participants now, none under way, none of them phase 3. Glioblastoma · AbbVie.
Among the 11 studies in Glioblastoma by AbbVie, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 3, and was the 11th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →None of the 11 studies in Glioblastoma by AbbVie is open now. The open studies under Glioblastoma, anywhere →
Of the 341 Glioblastoma studies recruiting now, 236 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 2
First in 2013; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 58 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Glioblastoma by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).
This Phase 3b open-label, randomized, exploratory study included 2 phases during the treatment period: chemoradiation therapy (radiation plus temozolomide [RT/TMZ]) and adjuvant therapy (TMZ). All participants received depatuxizumab mafodotin during both phases of the treatment period plus 1 of 3 prophylactic ophthalmologic treatments (standard steroids; standard steroids with vasoconstrictors and cold compress; and enhanced steroids with vasoconstrictors and cold compress. The study comprised a screening period of up to 7 weeks after surgery, a 6-week concomitant Chemoradiation Phase, an Adjuvant Phase beginning approximately 4 weeks after completion of chemoradiation, and a Follow-Up Phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days
Drug: Steroid eye drops · Drug: Depatuxizumab mafodotin · Drug: Temozolomide · Radiation: Radiation
Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).
Drug: Steroid eye drops · Drug: Vasoconstrictor eye drops · Other: Cold compress · Drug: Depatuxizumab mafodotin · Drug: Temozolomide · Radiation: Radiation
Enhanced steroid eye drops: 1 drop each eye, 6 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Ophthalmic Steroid Ointment; applied to each eye once daily before sleep, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. Cold compress was to be applied in increments no longer than 30 min (could be shorter if the patient is uncomfortable).
Drug: Steroid eye drops · Drug: Vasoconstrictor eye drops · Other: Cold compress · Drug: Ophthalmic steroid ointment · Drug: Depatuxizumab mafodotin · Drug: Temozolomide · Radiation: Radiation
Solution, eye drop
Solution, eye drop
Cold compress
Ointment
During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
Also known as: ABT-414
Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management
Inadequate control of ocular side effects (OSE) was defined as either a ≥ 3-line decline from baseline (≥ +0.3 on LogMAR scale) in visual acuity (with baseline correction determined at the screening ophthalmology visit)) or ≥ Grade 3 OSE severity on the Corneal Epithelial Adverse Event (CEAE) scale.
Time frame: Within 8 weeks after the initial dose of depatuxizumab mafodotin
Maximum Change From Baseline on the Logarithm of the Minimum Angle of Resolution (LogMAR) Scale
The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment. The baseline observation is defined as the last non-missing measurement collected prior to the first dose of depatuxizumab mafodotin.
Time frame: Within 8 weeks after the initial dose of depatuxizumab mafodotin
Time to Bandage Contact Lens (BCL) Intervention
The time to initiation of bandage contact lenses for those participants who required intervention due to inadequate control of ocular side effects (OSE) was calculated.
Time frame: Up to 9 months after the first dose of depatuxizumab mafodotin
Number of Participants With Depatuxizumab Mafodotin Dose Modifications Due to Ocular Side Effects (OSE)
Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs.
Time frame: From the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks
Cumulative Dose of Depatuxizumab Mafodotin Received During Chemoradiation and During Adjuvant Treatment
The cumulative dose of depatuxizumab mafodotin administered was tabulated.
Time frame: Up to 9 months
Treatment-Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit
The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).
Time frame: Up to 47 weeks
Change From Baseline In Logarithm of the Minimum Angle of Resolution (LogMAR) Scale After Bandage Contact Lens (BCL) Intervention
The change on the LogMAR Scale from last assessment prior to BCL intervention to 2 weeks after BCL intervention was calculated. The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.
Time frame: From the last assessment prior to BCL intervention to 2 weeks after BCL intervention
Percentage of Participants That Recovered to <3-line Decline From Baseline (≤ +0.3 LogMAR) in Visual Acuity After Bandage Contact Lens (BCL) Intervention
Recovery was defined as return to \<3-line decline from baseline (≤ +0.3 LogMAR) in visual acuity after BCL intervention.
Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention
Number of Participants With Depatuxizumab Mafodotin Dose Modifications to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention
Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs after BCL intervention.
Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention, up to 38 weeks
Time to Restart Depatuxizumab Mafodotin if Interrupted Due to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention
The time to restart depatuxizumab mafodotin treatment if it was interrupted due to ocular side effects after BCL Intervention was tabulated.
Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention
Treatment Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit After Bandage Contact Lens (BCL) Intervention
The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).
Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention, up to 38 weeks
Time to Ocular Side Effect (OSE) Symptom Resolution After Drug Discontinuation (Reversibility)
The time from discontinuation of depatuxizumab mafodotin to OSE symptom resolution (reversibility) was to be recorded.
Time frame: From the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks
Time to Re-initiation of Depatuxizumab Mafodotin After Dose Interruption
The time from dose interruption until re-initiation or permanent discontinuation of depatuxizumab mafodotin was to be recorded.
Time frame: Up to 9 months
| Milestone | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress | Untreated Participants |
|---|---|---|---|---|
| Started | 14 | 12 | 12 | 2 |
| Completed | 2 | 3 | 0 | 0 |
| Not completed | 12 | 9 | 12 | 2 |
| Withdrew: Withdrawal by subject | 5 | 2 | 5 | 1 |
| Withdrew: Progressive disease (per protocol) | 0 | 2 | 2 | 0 |
| Withdrew: Other, not specified | 6 | 4 | 5 | 1 |
| Withdrew: Left study due to covid-19 restrictions | 1 | 1 | 0 | 0 |
Inadequate control of ocular side effects (OSE) was defined as either a ≥ 3-line decline from baseline (≥ +0.3 on LogMAR scale) in visual acuity (with baseline correction determined at the screening ophthalmology visit)) or ≥ Grade 3 OSE severity on the Corneal Epithelial Adverse Event (CEAE) scale.
| percentage of participants | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Bilateral vision | 50.0 | 27.3 | 41.7 |
| Vision in worst eye | 64.3 | 72.7 | 50.0 |
The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment. The baseline observation is defined as the last non-missing measurement collected prior to the first dose of depatuxizumab mafodotin.
| units on a scale | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Bilateral vision | 0.353 ± 0.1888 | 0.402 ± 0.1985 | 0.272 ± 0.3888 |
| Vision in worst eye | 0.482 ± 0.2028 | 0.528 ± 0.3073 | 0.430 ± 0.5120 |
The time to initiation of bandage contact lenses for those participants who required intervention due to inadequate control of ocular side effects (OSE) was calculated.
| months | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Time to Bandage Contact Lens (BCL) Intervention | NA (1.1 to NA) | 3.6 (1.1 to NA) | 2.1 (1.1 to NA) |
Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs.
| Participants | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Number of Participants With Depatuxizumab Mafodotin Dose Modifications Due to Ocular Side Effects (OSE) | 2 | 3 | 2 |
The cumulative dose of depatuxizumab mafodotin administered was tabulated.
| mg/kg | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Cumulative Dose of Depatuxizumab Mafodotin Received During Chemoradiation and During Adjuvant Treatment | 8.5 ± 5.86 | 10.5 ± 7.35 | 7.0 ± 3.67 |
The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).
| Participants | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Week 1: Grade 0 | 10 | 8 | 5 |
| Week 1: Grade 1 | 1 | 3 | 1 |
| Week 3: Grade 0 | 4 | 5 | 7 |
| Week 3: Grade 1 | 10 | 6 | 3 |
| Week 3: Grade 2 | 0 | 0 | 1 |
| Week 5: Grade 0 | 1 | 0 | 2 |
| Week 5: Grade 1 | 7 | 5 | 6 |
| Week 5: Grade 2 | 1 | 3 | 2 |
| Week 5: Grade 3 | 4 | 2 | 2 |
| Week 7: Grade 0 | 0 | 0 | 2 |
| Week 7: Grade 1 | 3 | 4 | 0 |
| Week 7: Grade 2 | 4 | 6 | 5 |
| Week 7: Grade 3 | 2 | 0 | 2 |
| Week 9: Grade 0 | 1 | 0 | 1 |
| Week 9: Grade 1 | 1 | 2 | 0 |
| Week 9: Grade 2 | 3 | 5 | 4 |
| Week 9: Grade 3 | 2 | 0 | 1 |
| Week 11: Grade 0 | 0 | 0 | 1 |
| Week 11: Grade 1 | 2 | 1 | 0 |
| Week 11: Grade 2 | 2 | 0 | 3 |
| Week 11: Grade 3 | 1 | 0 | 1 |
| Week 11: Grade 4 | 1 | 0 | 0 |
| Week 13: Grade 1 | 1 | 0 | 1 |
| Adj Week 1: Grade 0 | 0 | 1 | 0 |
| Adj Week 1: Grade 1 | 1 | 3 | 2 |
| Adj Week 1: Grade 2 | 3 | 2 | 2 |
| Adj Week 1: Grade 3 | 1 | 0 | 0 |
| Adj Week 5: Grade 0 | 0 | 2 | 2 |
| Adj Week 5: Grade 1 | 1 | 3 | 0 |
| Adj Week 5: Grade 2 | 4 | 0 | 1 |
| Adj Week 5: Grade 3 | 1 | 1 | 0 |
| Adj Week 9: Grade 0 | 0 | 1 | 0 |
| Adj Week 9: Grade 1 | 0 | 2 | 1 |
| Adj Week 9: Grade 2 | 2 | 2 | 2 |
| Adj Week 9: Grade 3 | 1 | 1 | 0 |
| Adj Week 13: Grade 0 | 0 | 1 | 0 |
| Adj Week 13: Grade 1 | 0 | 2 | 0 |
| Adj Week 13: Grade 2 | 2 | 2 | 2 |
| Adj Week 13: Grade 3 | 1 | 0 | 0 |
| Adj Week 17: Grade 0 | 0 | 0 | 1 |
| Adj Week 17: Grade 1 | 0 | 1 | 0 |
| Adj Week 17: Grade 2 | 2 | 3 | 0 |
| Adj Week 21: Grade 1 | 0 | 0 | 1 |
| Adj Week 21: Grade 2 | 2 | 3 | 0 |
| Adj Week 25: Grade 1 | 0 | 2 | 0 |
| Adj Week 25: Grade 2 | 1 | 1 | 0 |
| Adj Week 29: Grade 2 | 1 | 0 | 0 |
| Adj Week 29: Grade 4 | 0 | 1 | 0 |
The change on the LogMAR Scale from last assessment prior to BCL intervention to 2 weeks after BCL intervention was calculated. The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.
| units on a scale | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Within 8 weeks of first dose: Bilateral vision | 0.325 ± 0.1248 | 0.13 ± 0.099 | 0.54 ± 0.1442 |
| Within 8 weeks of first dose: Vision in worst eye | 0.435 ± 0.0574 | 0.52 ± 0.3111 | 0.867 ± 0.2914 |
| Within 8 weeks of first adjuvant dose: Bilateral vision | -0.1 | 0.41 ± 0.2404 | — |
| Within 8 weeks of first adjuvant dose: Vision in worst eye | -0.1 | 0.33 ± 0.0141 | — |
Recovery was defined as return to \<3-line decline from baseline (≤ +0.3 LogMAR) in visual acuity after BCL intervention.
No measurements were reported for this outcome.
Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs after BCL intervention.
| participants | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Number of Participants With Depatuxizumab Mafodotin Dose Modifications to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention | 2 | 1 | 0 |
The time to restart depatuxizumab mafodotin treatment if it was interrupted due to ocular side effects after BCL Intervention was tabulated.
No measurements were reported for this outcome.
The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).
| Participants | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| Week 5: Grade 1 | 2 | 0 | 0 |
| Week 7: Grade 2 | 1 | 1 | 0 |
| Week 9: Grade 2 | 1 | 1 | 1 |
| Week 11: Grade 2 | 0 | 0 | 2 |
| Week 11: Grade 3 | 1 | 0 | 0 |
| Week 13: Grade 1 | 1 | 0 | 0 |
| Adj Week 1: Grade 1 | 0 | 0 | 1 |
| Adj Week 1: Grade 2 | 0 | 0 | 1 |
| Adj Week 5: Grade 0 | 0 | 1 | 1 |
| Adj Week 5: Grade 1 | 0 | 1 | 0 |
| Adj Week 5: Grade 2 | 1 | 0 | 1 |
| Adj Week 5: Grade 3 | 1 | 0 | 0 |
| Adj Week 9: Grade 0 | 0 | 1 | 0 |
| Adj Week 9: Grade 1 | 0 | 0 | 1 |
| Adj Week 9: Grade 2 | 0 | 0 | 1 |
| Adj Week 9: Grade 3 | 1 | 0 | 0 |
| Adj Week 13: Grade 0 | 0 | 2 | 0 |
| Adj Week 13: Grade 1 | 0 | 1 | 0 |
| Adj Week 13: Grade 2 | 1 | 0 | 1 |
| Adj Week 13: Grade 3 | 1 | 0 | 0 |
| Adj Week 17: Grade 1 | 0 | 1 | 0 |
| Adj Week 17: Grade 2 | 1 | 1 | 0 |
| Adj Week 21: Grade 2 | 2 | 1 | 0 |
| Adj Week 25: Grade 1 | 0 | 1 | 0 |
| Adj Week 25: Grade 2 | 1 | 0 | 0 |
| Adj Week 29: Grade 2 | 1 | 0 | 0 |
The time from discontinuation of depatuxizumab mafodotin to OSE symptom resolution (reversibility) was to be recorded.
No measurements were reported for this outcome.
The time from dose interruption until re-initiation or permanent discontinuation of depatuxizumab mafodotin was to be recorded.
No measurements were reported for this outcome.
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks. In addition, serious adverse events and protocol-related nonserious adverse events were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard Steroids | 1/14 (7.1%) | 6/14 (42.9%) | 14/14 (100%) |
| Standard Steroids + Vasoconstrictor + Cold Compress | 1/12 (8.3%) | 4/12 (33.3%) | 12/12 (100%) |
| Enhanced Steroids + Vasoconstrictor + Cold Compress | 1/12 (8.3%) | 4/12 (33.3%) | 12/12 (100%) |
| Event | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/14 | 1/12 | 0/12 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 1/14 | 1/12 | 1/12 |
| ULCERATIVE KERATITISEye disorders | 0/14 | 1/12 | 0/12 |
| PYREXIAGeneral disorders | 1/14 | 0/12 | 1/12 |
| EYE INFECTIONInfections and infestations | 0/14 | 1/12 | 0/12 |
| PNEUMONIAInfections and infestations | 0/14 | 1/12 | 0/12 |
| TUMOUR PSEUDOPROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/14 | 0/12 | 1/12 |
| HEADACHENervous system disorders | 0/14 | 0/12 | 1/12 |
| HEMIPARESISNervous system disorders | 1/14 | 1/12 | 1/12 |
| SEIZURENervous system disorders | 1/14 | 1/12 | 0/12 |
| Event | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress |
|---|---|---|---|
| FATIGUEGeneral disorders | 6/14 | 9/12 | 7/12 |
| NAUSEAGastrointestinal disorders | 6/14 | 6/12 | 3/12 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 3/14 | 5/12 | 3/12 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 2/14 | 5/12 | 3/12 |
| ALOPECIASkin and subcutaneous tissue disorders | 2/14 | 2/12 | 5/12 |
| CONSTIPATIONGastrointestinal disorders | 5/14 | 4/12 | 2/12 |
| VOMITINGGastrointestinal disorders | 5/14 | 1/12 | 1/12 |
| HEADACHENervous system disorders | 5/14 | 3/12 | 4/12 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 4/14 | 2/12 | 2/12 |
| LYMPHOCYTE COUNT DECREASEDInvestigations | 1/14 | 0/12 | 3/12 |
Safety population: All randomized participants who received at least 1 dose of depatuxizumab mafodotin
| Age, Continuous(years) | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress | Total |
|---|---|---|---|---|
| Mean | 47.6 ± 9.85 | 55.2 ± 10.53 | 57.3 ± 8.69 | 53.1 ± 10.39 |
| Sex: Female, Male(Participants) | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress | Total |
|---|---|---|---|---|
| Female | 3 | 4 | 1 | 8 |
| Male | 11 | 8 | 11 | 30 |
| Race/Ethnicity, Customized(Participants) | Standard Steroids | Standard Steroids + Vasoconstrictor + Cold Compress | Enhanced Steroids + Vasoconstrictor + Cold Compress | Total |
|---|---|---|---|---|
| White | 12 | 12 | 12 | 36 |
| Black or African American | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Jul 2018 to primary completion in Sep 2019, 13 months.
Results were first posted in Apr 2021, 1 year 7 months after primary completion. A results delay was requested in Aug 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Depatuxizumab mafodotin